# A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA

> **NCT07738822** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Cullinan Therapeutics Inc.** · enrollment: 72 (estimated)

## Conditions studied

- Immune Thrombocytopenia (ITP)
- Warm Autoimmune Hemolytic Anemia (WAIHA)

## Interventions

- **DRUG:** Velinotamig specified dose on specified days.

## Key facts

- **NCT ID:** NCT07738822
- **Lead sponsor:** Cullinan Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2029-01
- **Final completion:** 2031-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738822, "A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07738822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*